Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 1017-1022

  Peric, Mihaela ^a   Bozdogan, Bülent ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CLARITHROMYCIN; MACROLIDE; RIBOSOME PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG ACCUMULATION; DRUG INACTIVATION; GENE MUTATION; HAEMOPHILUS INFLUENZAE; METHYLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMES;

EID: 0037417016     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.1017-1022.2003     Document Type: Article

References (25)

1. Bingen, E., R. Leclercq, F. Fitoussi, N. Brahimi, B. Malbruny, D. Deforche, and R. Cohen. 2002. Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrob. Agents Chemother. 46:1199-1203.
2. Black, S. B., H. R. Shinefield, B. Fireman, and R. Hiatt. 1992. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. J. Infect. Dis. 165(Suppl. 1):S139-S143.
3. Canu, A., B. Malbruny, M. Coquemont, T. A. Davies, P. C. Appelbaum, and R. Leclercq. 2002. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:125-131.
4. Clark, C. L., B. Bozdogan, M. Peric, M. R. Jacobs, and P. C. Appelbaum. 2002. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. Antimicrob. Agents Chemother. 46:2956-2962.
5. Dagan, R., C. E. Johnson, S. McLinn, N. Abughali, J. Feris, E. Leibovitz, D. J. Burch, and M. R. Jacobs. 2000. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr. Infect. Dis. J. 19:95-104.
6. Depardieu, F., and P. Courvalin. 2001. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:319-323.
7. Doern, G. V., A. B. Brueggemann, G. Pierce, H. P. Holley, Jr., and A. Rauch. 1997. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. 41:292-297.
8. Gotfried, M. H. 2001. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. 111(Suppl. 9A):25S-29S.
9. Jacobs, M. R. 2001. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 7:589-596.
10. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 USA surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
11. Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34:482-492.
12. Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother, 35:1267-1272.
13. Lonks, J., J. Garau, L. Gomez, M. Xercavins, A. Ochoa De Echaguen, I. F. Gareen, P. T. Reiss, and A. A. Medeiros. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35:556-564.
14. Mitten, M. J., J. Meulbroek, M. Nukkala, L. Paige, K. Jarvis, A. Oleksijew, A. Tovcimak, L. Hernandez, J. D. Alder, P. Ewing, Y. S. Or, Z. Ma, A. M. Nilius, K. Mollison, and R. K. Flamm. 2001. Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob. Agents Chemother. 45:2585-2593.
15. Nagai, K., P. C. Appelbaum, T. A. Davies, L. M. Kelly, D. B. Hoellman, A. T. Andrasevic, L. Drukalska, W. Hryniewicz, M. R. Jacobs, J. Kolman, J. Miciuleviciene, M. Pana, L. Setchanova, M. K. Thege, H. Hupkova, J. Trupl, and P. Urbaskova. 2002. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and Eastern European countries. Antimicrob. Agents Chemother. 46:371-377.
16. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Pfaller, M. A., A. F. Ehrhardt, and R. N. Jones. 2001. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am. J. Med 111(Suppl. 9A):4S-12S.
18. Sanchez, L., W. Pan, M. Vinas, and H. Nikaido. 1997. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. 179:6855-6857.
19. Sokol, W. 2001. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. 111 (Suppl. 9A):19S-24S.
20. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.
21. Tait-Kamradt, A., T. Davies, M. Cronan, M. R. Jacobs, P. C. Appelbaum, and J. Sutcliffe. 2000. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44:2118-2125.
22. Tessier, P. R., M. K. Kim, W. Zhou, D. Xuan, C. Li, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1425-1434.
23. Wondrack, L., M. Massa, B. V. Yang, and J. Sutcliffe. 1996. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Antimicrob. Agents Chemother. 40:992-998.
24. Zgurskaya, H. I., and H. Nikaido. 2000. Multidrug resistance mechanisms: drug efflux across two membranes. Mol. Microbiol. 37:219-225.
25. Zimmermann, R. A., C. L. Thomas, and J. Wower. 1990. Structure and function of rRNA in decoding domain and at the peptidyltransferase center, p. 331-347. In W. E. Hill, A. Dahlberg, R. A. Garrett, P. B. Moore, D. Schlessinger, and J. R. Warner (ed.), The ribosome: structure, function, and evaluation. American Society for Microbiology, Washington, D.C.